MCID: PLS003
MIFTS: 21

Plasmacytic Leukemia

Categories: Blood diseases, Cancer diseases

Aliases & Classifications for Plasmacytic Leukemia

MalaCards integrated aliases for Plasmacytic Leukemia:

Name: Plasmacytic Leukemia 12 15
Leukemia, Plasma Cell 44 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9513
ICD10 33 C90.1 C90.10
ICD9CM 35 203.1
MeSH 44 D007952
NCIt 50 C3180
SNOMED-CT 68 39193004 95210003
UMLS 73 C0023484

Summaries for Plasmacytic Leukemia

MalaCards based summary : Plasmacytic Leukemia, also known as leukemia, plasma cell, is related to plasma cell leukemia and leukemia. An important gene associated with Plasmacytic Leukemia is FUT2 (Fucosyltransferase 2). The drugs Bortezomib and Dexamethasone have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and neutrophil.

Related Diseases for Plasmacytic Leukemia

Diseases related to Plasmacytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)
# Related Disease Score Top Affiliating Genes
1 plasma cell leukemia 11.9
2 leukemia 10.0
3 leukemia, acute myeloid 9.8
4 leukemia, chronic lymphocytic 2 9.7
5 leukemia, chronic lymphocytic 9.7
6 lymphoma, hodgkin, classic 9.7
7 polycythemia vera 9.7
8 lymphoma, non-hodgkin, familial 9.7
9 acute leukemia 9.7
10 lymphoma 9.7
11 chronic neutrophilic leukemia 9.7
12 lymphocytic leukemia 9.7
13 polycythemia 9.7
14 myeloid leukemia 9.7
15 leukemia, b-cell, chronic 9.7

Graphical network of the top 20 diseases related to Plasmacytic Leukemia:



Diseases related to Plasmacytic Leukemia

Symptoms & Phenotypes for Plasmacytic Leukemia

Drugs & Therapeutics for Plasmacytic Leukemia

Drugs for Plasmacytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
2
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
3
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2,Phase 1 1177-87-3
4
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
5
Fludarabine Approved Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
6
Busulfan Approved, Investigational Phase 2,Phase 1 55-98-1 2478
7
Lenalidomide Approved Phase 2,Phase 1 191732-72-6 216326
8
Cyclophosphamide Approved, Investigational Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
9
Melphalan Approved Phase 2,Phase 1 148-82-3 4053 460612
10
Lenograstim Approved, Investigational Phase 1, Phase 2,Phase 2 135968-09-1
11
Carmustine Approved, Investigational Phase 2,Phase 1 154-93-8 2578
12
Tacrolimus Approved, Investigational Phase 2,Phase 1 104987-11-3 445643 439492
13
Mechlorethamine Approved, Investigational Phase 2,Phase 1 51-75-2 4033
14
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
15
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
16
Cytarabine Approved, Investigational Phase 2,Phase 1 147-94-4 6253
17 Pomalidomide Approved Phase 2 19171-19-8
18 Ixazomib Approved, Investigational Phase 2,Phase 1 1072833-77-2
19
Daratumumab Approved Phase 2,Phase 1 945721-28-8
20
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
21
Gemcitabine Approved Phase 2 95058-81-4 60750
22 tannic acid Approved Phase 2
23
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
24
Promethazine Approved, Investigational Phase 2 60-87-7 4927
25
Allopurinol Approved Phase 2 315-30-0 2094
26
Benzocaine Approved, Investigational Phase 2 94-09-7, 1994-09-7 2337
27
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
28
Diphenhydramine Approved, Investigational Phase 2 147-24-0, 58-73-1 3100
29
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
30
Acetaminophen Approved Phase 2 103-90-2 1983
31
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
32
Everolimus Approved Phase 2 159351-69-6 6442177
33
Sirolimus Approved, Investigational Phase 2 53123-88-9 46835353 6436030 5284616
34
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1,Not Applicable 22916-47-8 4189
35
Vidarabine Approved, Investigational Phase 1, Phase 2 24356-66-9 32326 21704
36
Pegaspargase Approved, Investigational Phase 2 130167-69-0
37
Glycine Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 56-40-6 750
38
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 77-92-9 311
39
Doxil Approved June 1999 Phase 2,Phase 1 31703
40
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
41 Topoisomerase Inhibitors Phase 2,Phase 1
42 Antineoplastic Agents, Hormonal Phase 2,Phase 1
43 Anti-Inflammatory Agents Phase 2,Phase 1
44 Antiemetics Phase 2,Phase 1
45 HIV Protease Inhibitors Phase 2,Phase 1
46 Immunoglobulin A Phase 2
47 Gastrointestinal Agents Phase 2,Phase 1
48 glucocorticoids Phase 2,Phase 1
49 Hormone Antagonists Phase 2,Phase 1
50
protease inhibitors Phase 2,Phase 1

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia Unknown status NCT01328236 Phase 2 Bortezomib;Liposome doxorubicin;Dexamethasone
2 Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) Unknown status NCT01435720 Phase 1, Phase 2
3 Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia Completed NCT01553357 Phase 2 Lenalidomide, dexamethasone
4 Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70 Completed NCT02858999 Phase 2 PAD-VCD
5 Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants Completed NCT00307086 Phase 2 Bortezomib;Melphalan
6 A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma Completed NCT00821249 Phase 1, Phase 2 ARRY-520, KSP(Eg5) inhibitor; intravenous;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;Dexamethasone, steroid; oral
7 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Completed NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
8 Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia Recruiting NCT02547662 Phase 2 Dexamethasone;Ixazomib Citrate;Pomalidomide
9 MUK Nine b: OPTIMUM Treatment Protocol Recruiting NCT03188172 Phase 2 Cyclophosphamide;Bortezomib;Lenalidomide;Daratumumab;Dexamethasone;Melphalan;Filgrastim
10 Umbilical Cord Blood-Derived Natural Killer Cells, Elotuzumab, Lenalidomide, and High Dose Melphalan, Followed by Stem Cell Transplant in Treating Patients With Multiple Myeloma Recruiting NCT01729091 Phase 2 Lenalidomide;Melphalan
11 Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma Recruiting NCT02506959 Phase 2 Busulfan;Gemcitabine Hydrochloride;Melphalan;Panobinostat
12 Allo HSCT Using RIC for Hematological Diseases Recruiting NCT02661035 Phase 2 Allopurinol;Fludarabine;Cyclophosphamide;ATG;Tacrolimus;MMF
13 Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Recruiting NCT03314974 Phase 2
14 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus
15 Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Active, not recruiting NCT02556931 Phase 2 Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
16 Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer Active, not recruiting NCT00027820 Phase 1, Phase 2 Fludarabine Phosphate;Cyclosporine;Mycophenolate Mofetil
17 Cytokine-Treated Veto Cells in Treating Participants With Hematologic Malignancies Following Stem Cell Transplant Not yet recruiting NCT03622788 Phase 1, Phase 2 Cyclophosphamide;Fludarabine
18 Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen Terminated NCT00615589 Phase 2 Fludarabine/Busulfan x 4 days
19 Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies Terminated NCT00837200 Phase 2 Oncaspar, Doxil, Decadron
20 Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma Withdrawn NCT03100877 Phase 1, Phase 2 Cyclophosphamide;Lenalidomide;Melphalan
21 Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies Unknown status NCT00988013 Phase 1
22 A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Completed NCT01248923 Phase 1 ARRY-520, KSP(Eg5) inhibitor; intravenous;Bortezomib, proteasome inhibitor; intravenous or subcutaneous;Dexamethasone, steroid; oral;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous;ARRY-520, KSP(Eg5) inhibitor; intravenous;Bortezomib, proteasome inhibitor; intravenous or subcutaneous;Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous
23 Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Completed NCT00258245 Phase 1 arsenic trioxide;bortezomib;dexamethasone;thalidomide;Aspirin
24 Combination Chemotherapy and Donor Stem Cell Transplant Followed by Ixazomib Citrate Maintenance Therapy in Treating Patients With Relapsed High-Risk Multiple Myeloma Recruiting NCT02504359 Phase 1 Carmustine;Cytarabine;Etoposide;Ixazomib Citrate;Melphalan;Methotrexate;Tacrolimus
25 SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy Recruiting NCT02334865 Phase 1 Lenalidomide
26 Filanesib and Carfilzomib in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Active, not recruiting NCT01372540 Phase 1 Carfilzomib;Filanesib
27 MDM2 Inhibitor AMG-232, Carfilzomib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Suspended NCT03031730 Phase 1 Carfilzomib;Dexamethasone;Lenalidomide;MDM2 Inhibitor AMG-232
28 Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia Withdrawn NCT03591744 Phase 1 Bortezomib;Dexamethasone;Lenalidomide;Pegylated Liposomal Doxorubicin Hydrochloride
29 Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma Withdrawn NCT02315157 Phase 1 Bendamustine
30 High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia Recruiting NCT03389347 Not Applicable
31 Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases Recruiting NCT01962636 Not Applicable Fludarabine;Cyclophosphamide;Cyclosporine A;Mycophenylate mofetil
32 Registry for Adults With Plasma Cell Disorders (PCD's) Recruiting NCT03717844

Search NIH Clinical Center for Plasmacytic Leukemia

Cochrane evidence based reviews: leukemia, plasma cell

Genetic Tests for Plasmacytic Leukemia

Anatomical Context for Plasmacytic Leukemia

MalaCards organs/tissues related to Plasmacytic Leukemia:

41
Bone, Myeloid, Neutrophil

Publications for Plasmacytic Leukemia

Articles related to Plasmacytic Leukemia:

# Title Authors Year
1
The concentration of CD44 is increased in hematopoietic stem cell grafts of patients with acute myeloid leukemia, plasma cell myeloma, and non-Hodgkin lymphoma. ( 20586634 )
2010
2
ACUTE PLASMACYTIC LEUKEMIA WITH HYPERCALCEMIA. REPORT OF A CASE WITHOUT BONE LESIONS. ( 14255352 )
1965
3
Plasmacytic leukemia; report of a case. ( 14780368 )
1950

Variations for Plasmacytic Leukemia

Expression for Plasmacytic Leukemia

Search GEO for disease gene expression data for Plasmacytic Leukemia.

Pathways for Plasmacytic Leukemia

GO Terms for Plasmacytic Leukemia

Sources for Plasmacytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....